Abstract
Background: Osteosarcoma (OS) is a common bone malignant tumor, which is the eighth leading form of pediatric cancer. Despite the modern chemotherapeutic development of OS, a number of patients with OS have a high risk of lung metastasis and local relapse after chemotherapy.
Objective: This review study focused on the role of long non coding RNAs (lncRNAs) in OS progression, and presented update reports on OS treatment by targeting specific lncRNAs.
Method: We have acquired information on OS and lncRNAs from scientific databases like google scholar, pubmed and scopus, and reviewed for this study.
Results: The lncRNAs regulate a number of biological processes, and abnormal expression of lncRNAs could play role in many cancers and other human diseases. Interestingly, some lncRNAs can act as oncogenes, while some act as tumor suppressor genes. A number of studies revealed that targeting the specific lncRNAs by RNA interferance technology may provide a novel therapeutic strategy in the treatment of OS.
Conclusion: LncRNAs could be a promising biomarker and might be a potential therapeutic target in OS patients.
Keywords: Cancer therapeutics, diagnostic markers, long non coding RNA, osteosarcoma, pathological aspects, abnormal expression.
Anti-Cancer Agents in Medicinal Chemistry
Title:Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Volume: 17 Issue: 10
Author(s): Kaixiu Wang, Wei Jiang, Chao Cheng, Yusheng Li*Min Tu*
Affiliation:
- Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan 410078,China
- Department of Orthopaedics, Second People's Hospital of Jingmen, Jingmen, HuBei 448000,China
Keywords: Cancer therapeutics, diagnostic markers, long non coding RNA, osteosarcoma, pathological aspects, abnormal expression.
Abstract: Background: Osteosarcoma (OS) is a common bone malignant tumor, which is the eighth leading form of pediatric cancer. Despite the modern chemotherapeutic development of OS, a number of patients with OS have a high risk of lung metastasis and local relapse after chemotherapy.
Objective: This review study focused on the role of long non coding RNAs (lncRNAs) in OS progression, and presented update reports on OS treatment by targeting specific lncRNAs.
Method: We have acquired information on OS and lncRNAs from scientific databases like google scholar, pubmed and scopus, and reviewed for this study.
Results: The lncRNAs regulate a number of biological processes, and abnormal expression of lncRNAs could play role in many cancers and other human diseases. Interestingly, some lncRNAs can act as oncogenes, while some act as tumor suppressor genes. A number of studies revealed that targeting the specific lncRNAs by RNA interferance technology may provide a novel therapeutic strategy in the treatment of OS.
Conclusion: LncRNAs could be a promising biomarker and might be a potential therapeutic target in OS patients.
Export Options
About this article
Cite this article as:
Wang Kaixiu, Jiang Wei, Cheng Chao, Li Yusheng*, Tu Min*, Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (10) . https://dx.doi.org/10.2174/1871520617666170213122442
DOI https://dx.doi.org/10.2174/1871520617666170213122442 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine Serotonin and Cancer: What Is the Link?
Current Molecular Medicine The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Small Molecule Protein-Protein Inhibitors for the p53-MDM2 Interaction
Current Topics in Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Double Point Modified Analogs of Vitamin D as Potent Activators of Vitamin D Receptor
Current Pharmaceutical Design Finding Appropriate Signal Peptides for Secretory Production of Recombinant Glucarpidase: An <i>In Silico</i> Method
Recent Patents on Biotechnology New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism